Given the broad physiological roles of furin in processing multiple proproteins, systemic furin inhibition may result in off-target effects, highlighting the need for tumor-selective or pathway-focused therapeutic strategies that target downstream effectors such as TGF-β/ERK signaling rather than global furin blockade. The gene discussed is TGFB1; the disease is neoplasm.